News | July 08, 2007

Medtronic Launches Wireless ICDs in Japan

July 9, 2007 - Medtronic Inc. announced the commercial launch of its latest cardiac resynchronization therapy-defibrillator, the Concerto CRT-D, and its latest implantable cardioverter-defibrillator, the Virtuoso ICD, which are the first of their kind in the Japanese market.
The CRT-D devices are equipped with the functions of an ICD, while also providing cardiac resychronization therapy for patients suffering from heart failure. The Concerto and Virtuoso are the first devices in Japan with wireless functionality, designed to reduce follow-up and procedure times.
The implanted devices internally record the patient’s pulse, device therapies delivered and other data over a certain period of time. This information is then provide this information wirelessly. Device settings can also be performed using the wireless function.
The Concerto and Virtuoso deliver anti-tachycardia pacing (ATP), while simultaneously charging the capacitor to provide a shock, if needed. This means that if the arrhythmia is not terminated using ATP, the devices are able to deliver the electrical shock with no delay, giving patients access to the safe, painless ATP therapy while minimizing patient burden.
The Concerto and Virtuoso are also reportedly the first devices in Japan capable of measuring the impedance in the thoracic cavity between the device implanted below the clavicle and the lead implanted in the ventricle, allowing the device to record the level of fluid in the patient’s lungs.

For more information: www.medtronic.com

Related Content

Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init